OGEN (Oragenics) Short Percentage of Float

View and export this data going back to 2003. Start your Free Trial

What is Oragenics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Oragenics's Short Percentage of Float

For the Biotechnology subindustry, Oragenics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oragenics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oragenics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Oragenics's Short Percentage of Float falls into.

Save Embed

;

Save Embed

;

Oragenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

0A64:UK

Address

1990 Main Street, Suite 750, Sarasota, FL, USA, 34236

Website

https://www.oragenics.com

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Executives

Alan W Dunton	director	VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Fred Telling	director	501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119
John P Gandolfo	director	62 TERRACE ROAD, WAYNE NJ 07470
Cassidy Bruce A. Sr.	director	C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203
Janet Huffman	officer: CFO, Secretary and Treasurer	5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Robert C Koski	director, 10 percent owner	1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Michael O'keefe Sullivan	officer: CFO, Secretary and Treasurer	3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607
Joseph Hernandez	10 percent owner	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Koski Family Lp	10 percent owner	1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Alan Joslyn	director, officer: CEO and President	39 OLD RIDGEBURY ROAD, DANBURY CT 06810
Charles L Pope	director	4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Christine L Koski	director, 10 percent owner	1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243
Thomas L Koski	10 percent owner